Physician profile
Peter V Lang
NPI 1861581175
$11,064.68
in general payments reported to CMS, 2019-2025
36 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $3,005 · 2021: $3,082 · 2022: $810 · 2023: $922 · 2024: $1,117 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,210.07 | 2019-2025 | Livdelzi |
| Abbvie INC. | $866.22 | 2019-2025 | |
| Janssen Biotech, INC. | $533.11 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.65 | 2019-2025 | Xifaxan, Cycloset |
| Merck Sharp & Dohme LLC | $249.11 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $246.69 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $246.48 | 2021-2023 | Zeposia |
| Celgene Corporation | $220.36 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $191.85 | 2022-2024 | Rotatable Snare |
| Lilly USA, LLC | $184.87 | 2021-2024 | Omvoh, Zepbound, Mounjaro |
| Vivus LLC | $170.73 | 2022-2025 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $157.57 | 2019-2024 | |
| Novo Nordisk INC | $141.80 | 2023-2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $139.79 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $135.52 | 2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $133.29 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $124.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.86 | 2021-2025 | Eohilia, Entyvio |
| Janssen Scientific Affairs, LLC | $86.83 | 2021 | |
| Madrigal Pharmaceuticals | $76.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $72.65 | 2019 | |
| Redhill Biopharma INC. | $56.49 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $35.86 | 2019-2021 | |
| Ucb, INC. | $34.26 | 2025 | Bimzelx |
| Alfasigma USA, INC. | $33.00 | 2020 | |
| Olympus America INC. | $31.59 | 2019 | |
| Dexcom, INC. | $24.88 | 2021 | |
| Shionogi INC | $22.04 | 2019 | |
| Teleflex LLC | $21.38 | 2023 | Urolift |
| Perspectum Diagnostics Ltd | $19.58 | 2022 | |
| Braintree Laboratories, INC. | $19.31 | 2023 | Sutab |
| Teva Pharmaceuticals USA, INC. | $17.65 | 2024 | Simlandi |
| Supernus Pharmaceuticals, INC. | $17.40 | 2022 | |
| Edwards Lifesciences Corporation | $16.86 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $16.04 | 2023 | Inspire |
| Pfizer INC. | $14.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.